November 22, 2024 – Stockholm & Luxembourg
ClexBio is pleased to announce new investments by GG1978 and EQT Foundation. These investments represent a significant endorsement of ClexBio's mission to restore cell and tissue function through bioengineered tissue therapeutics and will fuel the company's next preclinical development milestones.
ClexBio has developed a differentiated, high-throughput approach for manufacturing perfusable tissues that have the potential of creating a paradigm shift in cell therapy. The company is currently expanding its pre-clinical data package across several programs and is establishing a presence in the US. Its initial focus is on the development of a hepatocyte-based liver product to restore function in end-stage liver disease patients. ClexBio’s multi-component approach holds promise for treating a wide range of chronic diseases, which the company is aiming to scale into a multi-indication tissue therapy platform.
Giammaria Giuliani, Founder of GG 1978 highlights: “ClexBio’s pioneering work in creating scalable, vascularized tissues for therapeutic purposes is setting a new standard in bioengineering. We believe ClexBio has uncovered a truly novel way of delivering cells to potentially create functional cures for chronic diseases by addressing some of the historical shortfalls of traditional cell therapy. We look forward to supporting their efforts to revolutionize treatment options in regenerative medicine and believe they can establish themselves as leader in this emerging field.”
EQT Foundation, the philanthropic arm of global private equity firm EQT, will leverage EQT’s broad network and expertise in healthcare and life sciences. “ClexBio’s breakthroughs in tissue engineering have the potential to help patients facing serious medical conditions receive better and more affordable treatments where options are often limited and very costly,” says Cilia Holmes Indahl, CEO of EQT Foundation. “We’ve been impressed by the team and are excited to support ClexBio in bringing next-generation tissue therapeutic solutions to patients who need them most”
Armend Hati, CEO & Founder of ClexBio emphasized: “We are thrilled to work with the innovative teams at GG1978 and EQT Foundation. Together, we will further our vision of bioengineered tissue therapeutics as a new modality for treating chronic diseases, moving closer to accessible, off-the-shelf therapies that can significantly improve patient outcomes.”
About GG 1978
GG1978 is a closed-ended investment fund focused on pharmaceuticals and biotechnologies. With investments in both gene and cell therapy, the fund aims to support some of the most groundbreaking developments happening in the pharmaceutical industry today.
About EQT Foundation
EQT Foundation is the philanthropic arm and long-term shareholder of the global investment organization EQT, acting as a guardian of EQT’s purpose and values. The Foundation supports scientists and entrepreneurs bringing breakthrough solutions from lab to market, combining EQT’s expertise with catalytic investments and grants. With a focus on supporting scientific progress in underfunded areas of climate and health, the Foundation provides a learning platform for EQT employees to engage in philanthropy and work collaboratively across the globe to make a positive impact.
About ClexBio
ClexBio is a pre-clinical stage regenerative medicine company with a breakthrough platform for scalable, high-throughput generation of therapeutic tissues. We represent the next generation of cell therapy, leveraging fully functional bioengineered tissues to elevate the restorative ability of cells and produce a new class of curative treatments for some of the world’s most challenging medical conditions.
For all the latest updates, visit clexbio.com or follow us on LinkedIn.
